Pharsight

Qbrelis patents expiration

QBRELIS IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10406199 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US10039800 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US9616096 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US10265370 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US9463183 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US11179434 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US9814751 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US10940177 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US11771733 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

Qbrelis is owned by Azurity.

Qbrelis contains Lisinopril.

Qbrelis has a total of 9 drug patents out of which 0 drug patents have expired.

Qbrelis was authorised for market use on 29 July, 2016.

Qbrelis is available in solution;oral dosage forms.

Qbrelis can be used as method of treatment of heart failure, acute myocardial infarction, method of treating hypertension.

The generics of Qbrelis are possible to be released after 06 November, 2035.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using LISINOPRIL ingredient

Market Authorisation Date: 29 July, 2016

Treatment: Acute myocardial infarction; Method of treating hypertension; Method of treatment of heart failure

Dosage: SOLUTION;ORAL

How can I launch a generic of QBRELIS before it's drug patent expiration?
More Information on Dosage

QBRELIS family patents

Family Patents